A blue book with the title "MESOTHELIOMA" in yellow letters, placed next to a medical prescription pad with "Rx" prominently displayed, and a stethoscope resting nearby on a wooden surface.
February 23, 2024

Breakthrough Drug Offers New Hope in the Fight Against Mesothelioma

But a new groundbreaking drug – pegargiminase (ADI-PEG20) – is being hailed as a breakthrough that could change the game for victims and families wrestling with this formidable disease.

Mesothelioma is also a notoriously difficult disease to beat. Although mesothelioma accounts for a relatively small number of cases, with about 3,000 diagnoses annually according to the American Cancer Society, its prognosis is grim. A mere 12.5% of those diagnosed with pleural mesothelioma survive beyond five years. This has bolstered the urgency of finding more effective treatments, and the hopeful optimism that’s swirling around a new promising drug.

The principle behind pegargiminase’s function is surprisingly simple. It works by depleting the amino acid arginine, which is critical for the survival and multiplication of mesothelioma cells that cannot produce arginine independently. This translates to a targeted approach that ‘starves’ the cancer cells while sparing the healthy ones.

And according to the findings of a recent phase 3 clinical trial for pegargiminase, it’s quite effective.

Professor Peter Szlosarek of Queen Mary’s Barts Cancer Institute, an architect of this research, hailed ADI-PEG20 as a life-improving measure for patients. Its wider applications in treating soft tissue cancers and certain brain cancers are also under close scientific scrutiny.

The legal landscape for mesothelioma victims is entwined firmly with their medical and emotional battles, and often requires them to navigate unfamiliar processes in the search for justice and compensation.

Recognizing the need for specialized legal support, our team at SWMW Law has devoted much of our practice to fighting for mesothelioma victims and their families across the country. This includes helping victims evaluate their options for pursuing claims filed with special trusts established by asbestos companies that went out of business or reorganized under U.S. bankruptcy law, or civil personal injury and wrongful death claims against solvent companies that negligently exposed victims to asbestos.